Related Experiment Video
Updated: May 28, 2026
04:50
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
Published on: January 17, 2025
Transplantation for cholangiocarcinoma
Howard C Masuoka1, Charles B Rosen
1Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, USA.
Clinics in Liver Disease
|October 29, 2011
Summary
Cholangiocarcinoma (CCA), a biliary cancer, can develop from chronic inflammation like primary sclerosing cholangitis (PSC). Curative options include surgery or liver transplant, while other treatments offer palliative care.
Area of Science:
- Hepatology
- Oncology
- Gastroenterology
Background:
- Cholangiocarcinoma (CCA) originates from the biliary epithelium.
- Primary sclerosing cholangitis (PSC) is a risk factor for CCA development due to chronic biliary inflammation.
- Early-stage extrahepatic CCA requires neoadjuvant therapy before surgical resection or liver transplantation.
Purpose of the Study:
- To outline the treatment landscape for cholangiocarcinoma.
- To highlight curative and palliative strategies for CCA patients.
- To emphasize the role of liver transplantation in specific CCA cases.
Main Methods:
- Review of current therapeutic modalities for CCA.
- Analysis of treatment outcomes for surgical and non-surgical candidates.
- Evaluation of neoadjuvant therapy in conjunction with liver transplantation.
Main Results:
- Surgical resection and liver transplantation are potentially curative for early extrahepatic CCA.
- Palliative options include biliary stenting, chemotherapy, radiation, and photodynamic therapy for non-surgical candidates.
- Liver transplantation is effective for unresectable hilar CCA, especially in PSC patients.
Conclusions:
- Treatment for CCA is tailored to disease stage and patient candidacy.
- Multidisciplinary approaches are crucial for managing CCA.
- Liver transplantation offers a viable curative option for select unresectable hilar CCA cases.